Search by Drug Name or NDC
NDC 10135-0667-01 Prazosin Hydrochloride 2 mg/1 Details
Prazosin Hydrochloride 2 mg/1
Prazosin Hydrochloride is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Marlex Pharmaceuticals Inc. The primary component is PRAZOSIN HYDROCHLORIDE.
MedlinePlus Drug Summary
Prazosin is used alone or in combination with other medications to treat high blood pressure. Prazosin is in a class of medications called alpha-blockers. It works by relaxing the blood vessels so that blood can flow more easily through the body. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys, and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
Related Packages: 10135-0667-01Last Updated: 02/05/2023
MedLinePlus Full Drug Details: Prazosin
Product Information
| NDC | 10135-0667 |
|---|---|
| Product ID | 10135-667_0a5d011d-308f-c100-e063-6294a90a9c6b |
| Associated GPIs | 36202030100110 |
| GCN Sequence Number | 000292 |
| GCN Sequence Number Description | prazosin HCl CAPSULE 2 MG ORAL |
| HIC3 | J7B |
| HIC3 Description | ALPHA-ADRENERGIC BLOCKING AGENTS |
| GCN | 01251 |
| HICL Sequence Number | 000091 |
| HICL Sequence Number Description | PRAZOSIN HCL |
| Brand/Generic | Generic |
| Proprietary Name | Prazosin Hydrochloride |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Prazosin Hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 2 |
| Active Ingredient Units | mg/1 |
| Substance Name | PRAZOSIN HYDROCHLORIDE |
| Labeler Name | Marlex Pharmaceuticals Inc |
| Pharmaceutical Class | Adrenergic alpha-Antagonists [MoA], alpha-Adrenergic Blocker [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA210971 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 10135-0667-01 (10135066701)
| NDC Package Code | 10135-667-01 |
|---|---|
| Billing NDC | 10135066701 |
| Package | 100 CAPSULE in 1 BOTTLE (10135-667-01) |
| Marketing Start Date | 2018-10-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |